Determination of Imatinib and Dasatinib in Leukemia Patients Plasma by HPLC-MS/MS

VernacularTitle:HPLC-MS／MS 法测定白血病患者血浆伊马替尼与达沙替尼浓度
Author: Lei WANG ; Fengye ZHOU ; Chunfei JIANG ; Beibei TAO ; Hongxing LIU
Publication Type:Journal Article
Keywords: dasatinib; imatinib; HPLC-MS/MS; TDM
From: Journal of Modern Laboratory Medicine 2016;(1):128-131
CountryChina
Language:Chinese
Abstract: Objective To develop a HPLC-MS/MS method for determination of Imatinib and Dasatinib in CML patient,and make it used in clinic trial.Methods The separation was performed on a Ultimate XB-C18 column with a mobile phase of water(containing 2 mmol/L ammonium acetate and 0.1 ml/dl formic acid)and methanol(containing 0.1 ml/dl formic acid). The way of eluting was gradient.Mass spectrum detection method was ESI positive ion mode and monitoring Imatinib m/z 494.5>394.3 and Dasatinib m/z 488.3>401.3.Results The standard curve of Imatinib was linear over the range of 0.05~7.5 μg/ml,Y =5.6×105 X+5× 103 (R =0.999 8).Thestandard curve of Dasatinib was linear over the range of 5~250 ng/ml,Y =211X+66.6(R=0.999 6).The relative recovery was among the range of 90%~107%.RSDs of intra-and inter-day validation were less than 10%.Conlusion This method is convenient,accurate and rapid,and can be used for the deter-mination of Imatinib and Dasatinib in clinic test.